Rochester, NY 7/14/2009 2:15:08 AM
Afternoon Stocks - TRGT - UPDATE 2-AstraZeneca to further develop Targacept's ADHD drug
Targacept, Inc.,TRGT
Targacept, Inc.,TRGT
COMPANY "In The News"
Targacept Inc (TRGT.O) said its licensing partner AstraZeneca (AZN.L) agreed to pay $10 million in milestone payment to further develop Targacept's experimental treatment for attention deficit/hyperactivity disorder (ADHD).
COMPANY DETAILS
Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of neuronal nicotinic receptor (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. It markets Inversine, which is for the management of moderately severe to severe hypertension and uncomplicated cases of malignant hypertension.
Last Trade: 2.90
Day's Range: 2.86 - 2.91
52wk Range: 1.40 - 10.11
Volume: 33,324
---
At WhisperfromWallStreet.com we specialize in understand the markets, particularly the penny stock market and understand what makes penny stocks increase. In a word it is exposure and by that we mean making the investing public aware of a particular stock, via an investor awareness campaign. Our tracking is second to none with our alerts in 2009 producing an average price gain of 80%+. If you'd like to track our results or receive your own alerts based on our experience, sign up now at... WhisperfromWallStreet.com
---
It's important that every investor be aware of our disclaimer which can be read in its entirety :
http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT NOTE: This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
